Ligand(LGND) - 2019 Q1 - Quarterly Report

For the Transition Period From ______ to ______ . Commission File Number: 001-33093 LIGAND PHARMACEUTICALS INCORPORATED (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________________ FORM 10-Q ________________________________________________________________________________________ x Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchang ...